Introduction
Levofloxacin (HR 355), a quinolone antibacterial, is the L-isomer of the racemate ofloxacin. 1 In general, it has a broad spectrum of activity and is equal to or up to fourfold more active than ofloxacin. 2 The aim of this study was to compare concentrations of levofloxacin at potential sites of respiratory infection, bronchial mucosa, epithelial lining fluid (ELF) and alveolar macrophages (AM) with simultaneous serum concentrations, up to 24 h after a single 500 mg oral dose, before bronchoscopy.
Materials and methods
A total of 35 patients (24 males, 11 females) undergoing elective diagnostic bronchoscopy were studied. All of the patients were over 18 years of age and all of the females were post-menopausal. The study was approved by the Hospital Ethicis Committee and all patients gave written informed consent.
Patients were excluded from the study if there was evidence of an active lung infection, if they were receiving antibiotic therapy or if their respiratory status was severely compromised. Subjects with significant renal impairment (determined by a serum creatinine of more than 220 mol/L), serious hepatic disease (reflected by any one of the following: transaminases 5 times the upper limit of the normal range, prothrombin time 50% of the control, bilirubin 85 mol/L or a history of encephalopathy). Patients with a history of allergy to quinolones, multiple drug sensitivity or photosensitivity were also excluded. Patients were also excluded if they were taking antacids, anticoagulants, iron salts or anti-epileptic drugs.
Dose regimen
This was an open study designed to measure concentrations of levofloxacin in bronchial tissues and fluids following the administration of a single 500 mg oral dose. After overnight fasting (depending on time of administration of drug) a single 500 mg oral dose was administered with 50 mL of non-aerated water. Patients were allocated randomly into six bronchoscopy groups as follows: Group 1, 0.5 h post-dose; Group 2, 1 h post-dose; Group 3, 2 h post-dose; Group 4, 4 h post-dose; Group 5, 6-8 h postdose; Group 6, 12-24 h post-dose.
Pre-medication
A standard pre-medication of 160 mg of 4% nebulized lignocaine, 0.6 mg atropine intramuscularly and 2.5-5 mg of intravenous midazolam was used. 
Sample collection and processing
A standard bronchoalveolar lavage (BAL) was performed using 200 mL of pre-warmed 0.9% sodium chloride (divided into four 50 mL aliquots) followed by gentle aspiration. The aspirate from the first 50 mL was discarded to avoid contamination of the sample with larger airway fluids and cells, 3 and any residual lignocaine which might affect the microbiological assay. The remaining three aspirates were pooled, and then divided into two Teflon containers (to avoid the loss of macrophages sticking to surfaces) for analysis. Immediately, in the endoscopy suite, a small sample was removed using silanized glassware and placed in an improved Neubauer counting chamber so that the number and type of cells present could be determined microscopically. The remaining sample was centrifuged at 400g for 5 min. After centrifugation the supernatant was separated immediately from the cells. Approximately 2 mL of the supernatant was removed for urea estimation. The remaining fluid was used to measure the concentration of levofloxacin present by freeze drying and reconstitution in HPLC grade distilled water to one-tenth of the original volume. Macrophages were ultrasonicated on ice in a known volume of chilled pH 7 phosphate buffer (100% duty cycles, Misonix Model XL2015, Life Science Laboratories, Luton, UK) before assay. Bronchial biopsy tissue was collected into a humidity chamber to avoid loss of moisture from the tissue before weighing. 4 Tissue was weighed (discarding any blood-stained tissue) and then ultrasonicated in buffer as previously described. Blood samples were taken at the end of the endoscopy for the assay of levofloxacin and urea. All samples for assay were stored at 4°C in the dark. With the exception of the lavage supernatant, all samples were assayed within 1 h of collection.
Microbiological assay
Concentrations of levofloxacin were measured using methodology previously externally validated by the R. W. Johnson Pharmaceutical Research Institute (Raritan, NJ, USA). Briefly, levels were determined using Iso-Sensitest agar (CM471i Unipath, Basingstoke, UK) and Escherichia coli 4004 (Bayer AG, Wuppertal, Germany). Calibrators, internal controls (fixed concentrations prepared from a different weighing of standard material) and quality assurance samples (variable concentrations similar to those expected from the patient samples), were prepared in pooled human serum (Bradsure Biologicals, Loughborough, UK) for human serum samples, pH 7 phosphate buffer for tissue and macrophage samples and 9% sodium chloride for the concentrated BAL samples. The calibrator concentrations were 0.125, 0.25, 0.5, 1 and 2 mg/L. The internal control samples were 1.5 and 0.2 mg/L and the quality assurance samples ranged from 0.15 to 1.8 mg/L. All samples were assayed in triplicate.
Assay plates were incubated for 18-20 h at 30°C and, after incubation, zones of inhibition were measured and calculated using an image analyser (Vidas 2.5, Imaging Associates, Thame, UK) programmed to construct a line of best fit using Bennett's calculation. 5 The lower limit of detection of the assay was 0.06 mg/L. All measurable concentrations were within the standard curve. Antibiotic concentration in the bronchial biopsy was calculated from the following equation:
where C A is the assayed concentration (mg/L), C T is the tissue concentration (in mg/kg), V is the diluent volume (in mL), and W is the weight of tissue (mg).
Calculation of antibiotic concentration in ELF
The urea concentration in the BAL was determined using a modified Sigma Diagnostic kit (UV-66, Sigma Chemicals, Poole, UK). The assay was linear over the range 0.01-0.09 mmol/L. The concentration of levofloxacin was calculated using the method described by Renard et al., 6 
Calculation of antibiotic concentration in macrophages
Using data derived by Johnson et al. 7 antibiotic concentration was determined assuming a mean AM cell volume of 2.48 L/10 6 cells.
Results
In Table I are summarized the results for the internal controls and quality assurance samples. These data confirm the reliability of the urea and microbiological assay results. The mean lavage volume, lavage urea, macrophage count and biopsy weight for the patient samples were Concentrations of levofloxacin in serum, biopsy, ELF and AM including site:serum ratios, are summarized in Table II . A plot of the corresponding data is shown in the Figure. The highest serum and biopsy concentration were seen 1 h post-dose (mean levels 6.6 mg/L and 8.3 mg/L, respectively). Mean ELF concentrations were very similar at 1, 2, 4 and 6-8 h post-dose (10.8, 9.0, 10.9 and 10.1 mg/L, respectively). Highest AM concentrations were recorded 2 h post-dose (mean 41.9 mg/L). In the 12-24 h group levofloxacin was not detected in biopsy samples in four of the six subjects and in ELF from three of the six subjects. Assuming a site:serum ratio of 1 for the biopsy samples and using the equation to calculate the amount of tissue needed to measure the level of levofloxacin, in all cases the amount of tissue obtained at biopsy was insufficient for quantification. Five subjects experienced mild headaches and eight subjects reported mild dizziness which the investigators felt may have been due to the antibiotic.
Discussion
This study has shown clinically significant pulmonary concentrations of levofloxacin following a single 500 mg dose. Concentrations were below the limit of quantification in the majority of ELF and biopsy samples taken in the 12-24 h post-dose group.
When the results obtained with levofloxacin are compared with those of ciprofloxacin and temafloxacin 8 comparable site:serum ratios (at 4 h post-dose) were found for all three agents except that the AM ratio for levofloxacin (9.1:1) was greater than those of ciprofloxacin (7.7:1) and temafloxacin (5.7:1).
The mean serum, biopsy, ELF and AM concentrations in all of the groups up to 6-8 h exceeded the MIC 90 s of the common respiratory pathogens (MIC 90 s for Streptococcus. pneumoniae, Moraxella catarrhalis and Haemophilus influenzae were 1, 0.06 and 0.015 mg/L respectively; unpublished data), by at least two-fold; this is important because earlier quinolones such as ciprofloxacin have only borderline activity. The concentration of levofloxacin within the AM suggests that the agent will be clinically active against 'atypical' pathogens associated with community-acquired infections (Chlamydia pneumoniae and Mycoplasma pneumoniae MIC 90 s of 0.5 mg/L). 9, 10 This study suggests that levofloxacin at a dose of 500 mg given twice a day should be effective in a wide range of lower respiratory tract infections. , Serum; , biopsy; v, epithelium lining fluid; , alveolar macrophages; BLQ, below limit of quantification.
